I actually did notice that but guess it didn't resonate with me as deeply because of the vagueness of the word some. I'll be curious to see the data as well. I guess at least with Gaucher they won't have the same EU problems as they did in Fabry.
Do you or genisi have any thoughts on the applicability to delivering other Enzymes orally?
News 
Market Data 
Discover 
